We are rapidly growing our development, regulatory and clinical expertise, along with world class manufacturing capabilities, to break existing oligopolies and make therapies affordable to patients globally. Biocon Biologics’ state-of-the-art manufacturing facilities are certified by various regulatory agencies from developed and emerging markets. With an unwavering commitment to quality, the Biocon Biologics has made significant investments in commercial scale, globally compliant manufacturing facilities across diverse technology platforms spanning insulin analogs, monoclonal antibodies and other recombinant proteins. We continue to expand our infrastructure in a capital-efficient, modular way.